Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma
Phase 3 SWOG Cancer Research Network trial, led by a City of Hope researcher, demonstrates one-year progression-free survival in 94% of patients with Stage 3 or 4 classic Hodgkin lymphoma who received a checkpoint inhibitor combined with chemotherapy
Jordan is the first country to provide iris recognition for digital transformation services
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
America’s Best Wings: Everything You Need to Know
The Renaissance deputy for Hautes-Pyrénées, Benoît Mournet, proposes to regulate the installation of doctors
VIDEO. Lying down for two months, he pedals in a centrifuge to advance space research
Cigarette butts thrown on the ground: are there enough ashtrays in Toulouse?
Marciac. The health antenna starts – ladepeche.fr
Vorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2 glioma with an...